We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Saliva Test Detects Alcohol Exposure

By LabMedica International staff writers
Posted on 25 Aug 2010
An innovative analytical test is capable of detecting Ethyl Sulfate (EtS) and Ethyl Glucuronide (EtG), produced by the body after alcohol exposure, in a simple saliva sample. More...


The Saliva-Alcohol Alco-Screen test is intended for use as a rapid, highly sensitive method to detect the presence of alcohol in saliva to provide an approximation of relative blood alcohol concentration, allowing for greater detection sensitivity than breath testing methods. The simple, one-step, two-minute test requires no instrumentation, calibration, or special training to be used effectively. For applications where a qualitative determination of blood alcohol concentration is required for forensic purposes, liquid chromatography-mass spectrometry-mass spectrometry (LC/MS/MS) technology is used for confirmation of the oral fluid test result.

Since the relationship between the amount of saliva alcohol and blood alcohol is 1:1, while with breath it is 0.000048:1, saliva serves as a more sensitive testing medium than breath. Another advantage of saliva analysis is ease of collection, since the sample is produced with direct observation that is not gender dependent (such as a urine test), and the oral fluid collector can be easily labeled and secured in a strict chain of custody procedures. Oral fluid samples also provide a good indication of recent drug use, as most drugs are present in the saliva for 2-4 days after use. The Saliva-Alcohol Alco-Screen test is a product of Forensic Laboratories (Denver, CO, USA).

"Our mass spectrometry division was one of the first to offer the quantitation of both EtG and EtS in urine,” said James Ruth, Ph.D., Forensic Laboratories' laboratory director. "Now we are the first to offer EtS in oral fluid.”

Both EtG and EtS are minor but important metabolites of alcohol, because they are more slowly eliminated from the body than alcohol itself and can thus be used to better document and detect alcohol. Both EtG and EtS have similar time spectra; one standard drink, in an average person, can be detectable for about 24 hours (using the lowest cutoffs of 100 ng/ml for EtG and 25 ng/ml for EtS), whereas urine alcohol will disappear following one drink within about 4 to 6 hours; after binge drinking EtG and/or EtS can be detected in urine for several days or more. However, while EtG is degraded in urine when certain bacteria are present (which can cause a false negative test), EtS has not been shown to be degraded by bacteria.

Related Links:

Forensic Laboratories



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Steam Sterilizer
Hi Vac II Line
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.